Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
No risks detected for INCY from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$75.99|
|52 Week High||US$70.97|
|52 Week Low||US$101.47|
|1 Month Change||1.99%|
|3 Month Change||-9.49%|
|1 Year Change||-12.44%|
|3 Year Change||14.12%|
|5 Year Change||-14.60%|
|Change since IPO||3,952.80%|
Recent News & Updates
Incyte: Not Exciting Yet, But Perhaps To Come
Incyte's shares have been struggling as diversification away from Jakafi/Jakavi remains a hot issue and challenge. Despite some recent approvals, this process takes time and moves slowly. With still quite a few years left until exclusivity of its blockbuster ends, and other approvals on the horizon, I am getting slowly more upbeat here.
|INCY||US Biotechs||US Market|
Return vs Industry: INCY underperformed the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: INCY underperformed the US Market which returned 33.8% over the past year.
Stable Share Price: INCY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: INCY's weekly volatility (3%) has been stable over the past year.
About the Company
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic.
Is Incyte undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INCY ($75.99) is trading below our estimate of fair value ($235.76)
Significantly Below Fair Value: INCY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INCY is poor value based on its PE Ratio (49.7x) compared to the US Biotechs industry average (25x).
PE vs Market: INCY is poor value based on its PE Ratio (49.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: INCY is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: INCY is overvalued based on its PB Ratio (5.7x) compared to the US Biotechs industry average (3.2x).
How is Incyte forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INCY's forecast earnings growth (36.9% per year) is above the savings rate (2%).
Earnings vs Market: INCY's earnings (36.9% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INCY's revenue (16.6% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: INCY's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INCY's Return on Equity is forecast to be high in 3 years time (31.5%)
How has Incyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INCY has high quality earnings.
Growing Profit Margin: INCY became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: INCY's earnings have grown by 11.8% per year over the past 5 years.
Accelerating Growth: INCY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: INCY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: INCY's Return on Equity (11.5%) is considered low.
How is Incyte's financial position?
Financial Position Analysis
Short Term Liabilities: INCY's short term assets ($2.6B) exceed its short term liabilities ($660.3M).
Long Term Liabilities: INCY's short term assets ($2.6B) exceed its long term liabilities ($308.4M).
Debt to Equity History and Analysis
Debt Level: INCY is debt free.
Reducing Debt: INCY has no debt compared to 5 years ago when its debt to equity ratio was 201.6%.
Debt Coverage: INCY has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INCY has no debt, therefore coverage of interest payments is not a concern.
What is Incyte current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INCY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INCY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INCY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INCY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Herve Hoppenot (61 yo)
Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commerci...
CEO Compensation Analysis
Compensation vs Market: Herve's total compensation ($USD16.38M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Herve's compensation has been consistent with company performance over the past year.
Experienced Management: INCY's management team is seasoned and experienced (6 years average tenure).
Experienced Board: INCY's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Incyte Corporation's employee growth, exchange listings and data sources
- Name: Incyte Corporation
- Ticker: INCY
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.781b
- Shares outstanding: 220.84m
- Website: https://www.incyte.com
Number of Employees
- Incyte Corporation
- 1801 Augustine Cut-Off
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:06|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.